iMDx posts Q2 loss as FDA review of GraftAssureDx continues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ACCV
2. GMAB
3. IVBIY
4. IIB:IN
5. AZN
6. DRRD:IN
7. SMMT
8. RDY
9. CART
10. CLYM

Go back to iMDx posts Q2 loss as FDA review of GraftAssureDx continues

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

August 10, 2026 4:05 PM EDT

Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunityStrong head-to-head data drive kitted customer interest

NASHVILLE, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results:

Fellow... More